AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 171 min read$GLUE

Warmuth Markus sold $220K of GLUE

Warmuth Markus (President & CEO) sold 9,500 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.18 ($0.22M total) on 2026-07-16.

Original reporting
SEC EDGAR · Warmuth Markus
Published Jul 17, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GLUE
Neutral
medium confidence
Mentioned
$GLUE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not change the company’s fundamentals.

03

What to watch

The article does not state whether the CEO has other holdings, prior sale patterns, or tax-related reasons; absence of a 10b5-1 plan does not prove intent.

Relevance 4/10Novelty 3/10Timing: after-hours filing timestamp on 2026-07-17 for a sale dated 2026-07-16

Background

The article is an SEC Form 4 insider transaction disclosure for Monte Rosa Therapeutics, Inc. (GLUE).

Company-level read

Ticker impact

$GLUENeutralMedium confidence
Context

SEC Form 4 shows GLUE CEO Warmuth sold 9,500 shares on 2026-07-16 for about $220.2K at $23.1809.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing discloses transaction size, price, and absence of a pre-arranged 10b5-1 plan, but provides no new company-specific operating or financial information.

Market effects

Sector

No clear sector read-through from a single CEO sale filing.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification or liquidity needs and does not necessarily signal reduced confidence in the business.

Key entities

  • issuer
    GLUE

    Monte Rosa Therapeutics, Inc., the company whose CEO filed the Form 4 insider sale.

  • insider
    Warmuth Markus

    President and CEO who sold 9,500 shares on 2026-07-16.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GLUE insider trading history →

Related articles

SEP 13
$NVSMed

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Monte Rosa Therapeutics (GLUE) received a $50M milestone payment from Novartis (NVS) for the first patient dosed in a Phase 2 trial of MRT-6160 for Sjögren’s disease. The deal could be worth up to $2.1B. Monte Rosa reported Q2 2026 revenue of $9M, up from $23.2M a year earlier, with a net loss of $43.4M. The company has multiple clinical trials ongoing and $626M in cash.

insidermonkey.com3 min
SEP 8
$GLUEMedAI 8/10

Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa Therapeutics (GLUE) announced that Novartis has initiated a Phase 2 study for MRT-6160 (DDY391) in Sjögren's disease patients. Monte Rosa will receive a $50 million milestone payment. The study is part of a global license agreement where Novartis has exclusive rights to develop and commercialize VAV1 MGDs, with Monte Rosa eligible for up to $2.1 billion in milestones.

finanznachrichten.de2 min
SEP 8
$NVSMedAI 8/10

Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease

Novartis (NVS) has begun a Phase 2 study of MRT-6160 for Sjögren’s disease. Monte Rosa Therapeutics (GLUE) will receive a $50M milestone payment. The study aims to evaluate efficacy, safety, and tolerability of the treatment. MRT-6160 is a VAV1-directed molecular glue degrader. Novartis holds exclusive rights under a licensing agreement, with Monte Rosa eligible for up to $2.1B in milestones.

investing.com2 min